O-PCPr Stats & Data

Identity and naming: O‑PCPr is 2′‑Oxo‑PCPr (2‑keto‑PCPr), an arylcyclohexylamine closely related to O‑PCE and PCP analogs; community threads reported it emerging after late‑2024 mislabeling as O‑PCE/O‑PCP. Mislabeling is common in this class—use drug checking and perform an allergy test before any psychoactive dose. Community reports describe a short‑to‑moderate duration dissociative with heavy body load, motor incoordination, and intermittent euphoria; sensitivity varies widely, so start low and wait a full onset window (at least 60–120 minutes oral, 45–60 minutes IN) before considering any redose. Dissociatives can aggravate lower urinary tract symptoms; ketamine‑like urological complications (including cystitis) are dose/frequency‑related—prioritize spacing (≥2–4 weeks), hydration, and early cessation if urinary discomfort, urgency, or pain occurs. Combining dissociatives with other CNS depressants (alcohol, benzos, GHB/GBL) markedly increases risks of blackout, aspiration, and accidents; stimulants raise cardiovascular strain and can precipitate agitation or manic states; avoid tramadol due to seizure risk and serotonergic complications. Use precise measurement: 0.001 g scales and volumetric dosing reduce dosing error and support allergy testing (e.g., ≤1 mg) when a lab result is unavailable. Expect impaired coordination and lingering fog; do not drive or perform safety‑critical tasks until fully baseline the next day. Market reports have noted bladder irritation and supply confusion (e.g., O‑PCE or O‑PCP sold instead); reagent tests are insufficient—seek lab‑based drug checking where available.